The most common mistake right now is treating the GLP-1 cancer signal as if it were a kidney-trial result. A viral post from Dr. William Li claims GLP-1 drugs were associated with 30–50% lower colon cancer recurrence, along with signals of fewer metastases across data from 30 million users. That is a social-media claim.
Social-media cancer-recurrence signals are not kidney-trial evidence; peer-reviewed outcome data must be tracked before clinical conclusions.
sift. reads hundreds of sources so you don't have to, and sends one issue you can actually finish. No daily noise. Unsubscribe anytime.